Market Overview

UBS: Biotech Will Continue To Outperform In 2015

UBS: Biotech Will Continue To Outperform In 2015

In a new report, UBS analyst Matthew Roden discusses the firm’s bullish outlook for biotech stocks. Biotech has had a strong run so far this year, but Roden still sees gas in the tank for several names.

Three Drivers

UBS sees three drivers for biotech outperformance in the second half of the year. First, the firm is predicting that most of the larger names should beat consensus earnings estimates in Q3 and Q4.

Second, the firm sees big catalysts on the way for several names in the second half of the year that could drive prices higher. The report names Incyte Corp (NASDAQ: INCY), BioMartin Pharmaceutical Inc (NASDAQ: BMRN), Prothena Corp Plc (NASDAQ: PRTA), Puma Biotechnology Inc (NYSE: PBYI), Achillion Pharmaceuticals Inc (NASDAQ: ACHN) and Medivation Inc (NASDAQ: MDVN) as second-half catalyst plays.

Finally, Roden mentions the continuing appetite for biotech M&A as a share price driver for the rest of the year. He believes that large cap biotech and pharma companies are still looking to make asset acquisitions, and share prices will likely remain elevated in that type of environment.

Buying Opportunity

Biotech stocks have been hit relatively hard during the recent market pullback. While Roden stops short of saying the worst is over at this point, he does believe that the dip has provided a buying opportunity for certain names.

Top Picks

UBS believes that there is little downside risk remaining in Gilead Sciences Inc (NASDAQ: GILD) and names the stock its top large cap biotech pick for the second half of the year. Medivation and BioMartin are UBS’s top two midcap picks, and Prothena is its top small cap play.

Latest Ratings for GILD

Jul 2019MaintainsNeutral
Jul 2019MaintainsStrong Buy
Jul 2019UpgradesOutperformTop Pick

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: BiotechAnalyst Color Biotech Long Ideas Top Stories Analyst Ratings Trading Ideas General Best of Benzinga


Related Articles (ACHN + BMRN)

View Comments and Join the Discussion!

Summit Research Henry Guo Lowers EPS And Rev Estimates For FY 2016/2017, Reiterates Buy, Lowers PT To $81 From $91

As Consumers Get Smarter, So Do Barcodes